Pub Date : 1900-01-01DOI: 10.25179/tjem.2019-64815
S. Hepşen, M. Ozbek, E. Sencar, P. Akhanlı, A. Arıkök, D. Şeker, I. Unsal, E. Çakal
{"title":"Retroperitoneal Castleman Disease Mimicking Paraganglioma in a Patient with Klinefelter Syndrome: A Case Report","authors":"S. Hepşen, M. Ozbek, E. Sencar, P. Akhanlı, A. Arıkök, D. Şeker, I. Unsal, E. Çakal","doi":"10.25179/tjem.2019-64815","DOIUrl":"https://doi.org/10.25179/tjem.2019-64815","url":null,"abstract":"","PeriodicalId":425605,"journal":{"name":"The Turkish Journal of Endocrinology and Metabolism","volume":"281 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131473282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.25179/tjem.2021-82251
M. Yazidi, Rym Ben Othmane, N. Mansour, I. Oueslati, F. Chaker, M. Chihaoui
Objective: The treatment of Graves’ disease (GD) with antithyroid drugs (ATD) is associated with a risk of relapse. The rate and predictive factors of GD are controversial. This study aimed to assess the relapse rate after the withdrawal of ATD in patients with GD, as well as to identify its predictive factors. Material and Methods: This was a retrospective cohort study covering 35 patients with GD that were treated with ATD. Relapse was defined as the state when hyperthyroidism was detected after the withdrawal of medical therapy. Relapse was studied by establishing the survival curve according to Kaplan-Meier’s method. The Log-Rank test was used to compare the survival curves according to the clinical, biological, and therapeutic parameters of the patients. Results: The mean follow-up time after the withdrawal of ATD was 32.8±28.8 months. Relapse was observed in 13 patients (37%) after an average time of 7.8±8.8 months of ATD discontinuation. Factors associated with the risk of relapse were smoking (p=0.08), family history of thyroid disease (p=0.03), the presence of a triggering factor (p=0.004), FT4 level at the time of diagnosis at >2.3 times the normal range (p=0.002), thyroid-stimulating hormone level less than 0.76 mIU/L at three months after ATD withdrawal (p=0.05), and a benzylthiouracil dose of >125 mg/day at the time of ATD discontinuation (p=0.02). Conclusion: Relapse in patients with GD after the withdrawal of ATD is observed in almost a third of the patients. Identification of patients at a high risk of relapse is necessary to indicate radical treatment.
{"title":"Risk Factors for the Relapse of Graves’ Disease Following Withdrawal of Antithyroid Drugs","authors":"M. Yazidi, Rym Ben Othmane, N. Mansour, I. Oueslati, F. Chaker, M. Chihaoui","doi":"10.25179/tjem.2021-82251","DOIUrl":"https://doi.org/10.25179/tjem.2021-82251","url":null,"abstract":"Objective: The treatment of Graves’ disease (GD) with antithyroid drugs (ATD) is associated with a risk of relapse. The rate and predictive factors of GD are controversial. This study aimed to assess the relapse rate after the withdrawal of ATD in patients with GD, as well as to identify its predictive factors. Material and Methods: This was a retrospective cohort study covering 35 patients with GD that were treated with ATD. Relapse was defined as the state when hyperthyroidism was detected after the withdrawal of medical therapy. Relapse was studied by establishing the survival curve according to Kaplan-Meier’s method. The Log-Rank test was used to compare the survival curves according to the clinical, biological, and therapeutic parameters of the patients. Results: The mean follow-up time after the withdrawal of ATD was 32.8±28.8 months. Relapse was observed in 13 patients (37%) after an average time of 7.8±8.8 months of ATD discontinuation. Factors associated with the risk of relapse were smoking (p=0.08), family history of thyroid disease (p=0.03), the presence of a triggering factor (p=0.004), FT4 level at the time of diagnosis at >2.3 times the normal range (p=0.002), thyroid-stimulating hormone level less than 0.76 mIU/L at three months after ATD withdrawal (p=0.05), and a benzylthiouracil dose of >125 mg/day at the time of ATD discontinuation (p=0.02). Conclusion: Relapse in patients with GD after the withdrawal of ATD is observed in almost a third of the patients. Identification of patients at a high risk of relapse is necessary to indicate radical treatment.","PeriodicalId":425605,"journal":{"name":"The Turkish Journal of Endocrinology and Metabolism","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130870777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.25179/tjem.2020-79546
N. Yasar, D. Konukoğlu
{"title":"Plasma Levels of Soluble P-Selectin, Beta-Thromboglobulin and Platelet Indices in Patients With Prediabetes: Effects of Acute Hyperglycemic Stress","authors":"N. Yasar, D. Konukoğlu","doi":"10.25179/tjem.2020-79546","DOIUrl":"https://doi.org/10.25179/tjem.2020-79546","url":null,"abstract":"","PeriodicalId":425605,"journal":{"name":"The Turkish Journal of Endocrinology and Metabolism","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131032635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.25179/TJEM.2018-63547
Sara Saniee, A. Zare, Afsaneh Radmehr
{"title":"Thyroid Dysfunction in Alopecia Areata","authors":"Sara Saniee, A. Zare, Afsaneh Radmehr","doi":"10.25179/TJEM.2018-63547","DOIUrl":"https://doi.org/10.25179/TJEM.2018-63547","url":null,"abstract":"","PeriodicalId":425605,"journal":{"name":"The Turkish Journal of Endocrinology and Metabolism","volume":"83 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125101276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.25179/tjem.2019-65625
R. Bozbulut, Esra Döğer, A. Bideci, O. Çamurdan, P. Cinaz
{"title":"Low-Carbohydrate Diets and Type 1 Diabetes","authors":"R. Bozbulut, Esra Döğer, A. Bideci, O. Çamurdan, P. Cinaz","doi":"10.25179/tjem.2019-65625","DOIUrl":"https://doi.org/10.25179/tjem.2019-65625","url":null,"abstract":"","PeriodicalId":425605,"journal":{"name":"The Turkish Journal of Endocrinology and Metabolism","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132712520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.25179/tjem.2020-78997
Hatice Özişik, Banu SARER YÜREKLİ, Y. Ertan, C. Eraslan, E. Özgiray, F. Saygili
Introduction Pituitary adenomas producing more than one pituitary hormone are defined as plurihormonal pituitary adenomas (PPA) according to the 2017 World Health Organization (WHO) classification of pituitary tumors (1). While the majority of functioning pituitary adenomas produce a single hormone, an imWe would like to draw the attention of the readers to Pit-1 positive giant macroadenomas in this work. A 62-year-old male patient was admitted to the hospital due to his vision loss and blurred vision in the left eye. His pituitary magnetic resonance imaging revealed the presence of a diffuse and homogeneous mass lesion originating from the pituitary gland having grade 4 invasion into the bilateral cavernous sinus and eroding the base of the sella. He consulted our department before his operation in 2016. Laboratory examination revealed that pituitary hormone levels were within normal ranges while the testosterone level [total testosterone 0.27 ng/mL (2.8-8)] was low. Pathological findings revealed a pituitary adenoma that displayed focal immunoreactivity to thyrotrophin, growth hormone, and prolactin. While the main prevalence and the basic mechanism of plurihormonal pituitary adenomas are not clear, one of the hypotheses is based on the role of divergent transcription factors such as Pit-1. According to this condition, we should perform a complete biochemical and histologic evaluation in patients with pituitary adenomas.
{"title":"A Case of Plurihormonal Pituitary Giant Macroadenoma","authors":"Hatice Özişik, Banu SARER YÜREKLİ, Y. Ertan, C. Eraslan, E. Özgiray, F. Saygili","doi":"10.25179/tjem.2020-78997","DOIUrl":"https://doi.org/10.25179/tjem.2020-78997","url":null,"abstract":"Introduction Pituitary adenomas producing more than one pituitary hormone are defined as plurihormonal pituitary adenomas (PPA) according to the 2017 World Health Organization (WHO) classification of pituitary tumors (1). While the majority of functioning pituitary adenomas produce a single hormone, an imWe would like to draw the attention of the readers to Pit-1 positive giant macroadenomas in this work. A 62-year-old male patient was admitted to the hospital due to his vision loss and blurred vision in the left eye. His pituitary magnetic resonance imaging revealed the presence of a diffuse and homogeneous mass lesion originating from the pituitary gland having grade 4 invasion into the bilateral cavernous sinus and eroding the base of the sella. He consulted our department before his operation in 2016. Laboratory examination revealed that pituitary hormone levels were within normal ranges while the testosterone level [total testosterone 0.27 ng/mL (2.8-8)] was low. Pathological findings revealed a pituitary adenoma that displayed focal immunoreactivity to thyrotrophin, growth hormone, and prolactin. While the main prevalence and the basic mechanism of plurihormonal pituitary adenomas are not clear, one of the hypotheses is based on the role of divergent transcription factors such as Pit-1. According to this condition, we should perform a complete biochemical and histologic evaluation in patients with pituitary adenomas.","PeriodicalId":425605,"journal":{"name":"The Turkish Journal of Endocrinology and Metabolism","volume":"75 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114859275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.25179/tjem.2018-62120
D. Etik, M. Erdoğan
D O I: 10 .2 51 79 /t je m .2 01 862 12 0 Objective: Iron and iodine, which are the two important micronutrients, are still deficient in a large number of women worldwide. This study aimed to examine the thyroid volumes of iron deficient, anemic women before and after correction of the anemia in a mildly iodine deficient environment. Material and Methods: Sixty six women aged 18-45 years were prospectively enrolled in this study. Inclusion criteria included serum hemoglobin (Hb) level <11.0 g/dL, ferritin level <13 ng/mL, thyroid hormones within normal reference ranges and negative thyroid antibodies. Oral iron supplement (567 mg ferrous sulfate, twice a day) for six months was prescribed and strongly recommended. All patients were re-evaluated at the end of the iron treatment. Results: Initially, the median (minimum/maximum) Hb and ferritin levels of patients were 10.2 g/dL (5.6/11.1) and 3.95 ng/mL (0.44/10.7), respectively. Six months later, median Hb and ferritin values increased significantly to 13.15 g/dL (9.3/15.6) (p<0.001) and 19.575 ng/mL (3.74/79) (p<0.001) respectively. Median thyroid volume decreased significantly from 15.705 mL (7.15/54.2) to 13.212 mL (6.11/52.8) (p<0.001). The patients were grouped according to the improvements in Hb and ferritin levels, initial thyroid gland volume, and response to the treatment. The reduction in thyroid gland size, at the end of the treatment, was more significant in patients with improvement in both Hb and ferritin levels as compared to those with improvement only in Hb levels (p<0.05). Conclusion: Iron may be responsible for efficient organification of iodine, active iodine utilization from thyroglobulin, and control of hyperkinetic blood-flow to the thyroid gland. The findings of this study support that other than iodine, iron supplementation has a significant effect on the regression of thyroid volume in women with iron deficiency anemia.
{"title":"The Effect of Treatment of Iron Deficiency Anemia on Thyroid Volume","authors":"D. Etik, M. Erdoğan","doi":"10.25179/tjem.2018-62120","DOIUrl":"https://doi.org/10.25179/tjem.2018-62120","url":null,"abstract":"D O I: 10 .2 51 79 /t je m .2 01 862 12 0 Objective: Iron and iodine, which are the two important micronutrients, are still deficient in a large number of women worldwide. This study aimed to examine the thyroid volumes of iron deficient, anemic women before and after correction of the anemia in a mildly iodine deficient environment. Material and Methods: Sixty six women aged 18-45 years were prospectively enrolled in this study. Inclusion criteria included serum hemoglobin (Hb) level <11.0 g/dL, ferritin level <13 ng/mL, thyroid hormones within normal reference ranges and negative thyroid antibodies. Oral iron supplement (567 mg ferrous sulfate, twice a day) for six months was prescribed and strongly recommended. All patients were re-evaluated at the end of the iron treatment. Results: Initially, the median (minimum/maximum) Hb and ferritin levels of patients were 10.2 g/dL (5.6/11.1) and 3.95 ng/mL (0.44/10.7), respectively. Six months later, median Hb and ferritin values increased significantly to 13.15 g/dL (9.3/15.6) (p<0.001) and 19.575 ng/mL (3.74/79) (p<0.001) respectively. Median thyroid volume decreased significantly from 15.705 mL (7.15/54.2) to 13.212 mL (6.11/52.8) (p<0.001). The patients were grouped according to the improvements in Hb and ferritin levels, initial thyroid gland volume, and response to the treatment. The reduction in thyroid gland size, at the end of the treatment, was more significant in patients with improvement in both Hb and ferritin levels as compared to those with improvement only in Hb levels (p<0.05). Conclusion: Iron may be responsible for efficient organification of iodine, active iodine utilization from thyroglobulin, and control of hyperkinetic blood-flow to the thyroid gland. The findings of this study support that other than iodine, iron supplementation has a significant effect on the regression of thyroid volume in women with iron deficiency anemia.","PeriodicalId":425605,"journal":{"name":"The Turkish Journal of Endocrinology and Metabolism","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125464528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.25179/tjem.2021-86594
Ö. Topaloğlu, Sakin Tekin, Seda Nur Topaloğlu, T. Bayraktaroğlu
Subacute thyroiditis (SAT) has been recently associated with severe acute respiratory syndrome-coronavirus-2 infection or vaccines against it. We report a case of a 41-year-old male patient who developed persistent SAT after the coronavirus disease-2019 (COVID-19) vaccination. He presented with sore throat and neck pain after the first dose of the COVID-19 vaccine (CoronaVac®). There was no history of a recent viral infection. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were elevated, thyroidstimulating hormone (TSH) and free thyroxine (fT4) were normal, COVID-19 polymerase chain reaction test was negative, and sonography showed thyroiditis in the right lobe. The symptoms resolved after treatment with methylprednisolone. However, 2 weeks after the second dose of the vaccine, the patient suffered from neck pain and hoarseness. TSH and fT4 were normal, but anti-thyroid peroxidase (anti- TPO), anti-thyroglobulin (anti-Tg), ESR, and CRP were elevated. Sonography revealed thyroiditis in the left lobe. The patient was treated with ibuprofen. On follow-up, hypothyroidism was diagnosed, and levothyroxine started. Hence, the clinicians should suspect the possibility of SAT in the vaccinated subjects. (English) [ FROM AUTHOR] Subakut tiroidit (SAT), son zamanlarda şiddetli akut solunum sendromu-koronavirüs-2 enfeksiyonu veya buna karşı geliştirilen aşılarla ilişkilendirilmektedir. Koronavirüs hastalığı- 2019 [coronavirus disease-2019 (COVID-19)] aşılaması sonrasında persistan SAT gelişen 41 yaşında erkek hastamızı sunuyoruz. COVID-19 aşısının (CoronaVac®) ilk dozundan sonra boğaz ağrısı ve boyun ağrısı ile başvurdu. Yakın zamanda viral enfeksiyon öyküsü yoktu. Eritrosit sedimentasyon hızı (ESH) ve C-reaktif protein (CRP) yüksekti, tiroidstimüle edici hormon (TSH) ve serbest tiroksin (sT4) normaldi, COVID-19 polimeraz zincir reaksiyonu testi negatifti ve sonografide sağ lobta tiroidit mevcuttu. Metilprednizolon tedavisi ile semptomlar geriledi. Ancak aşının 2. dozundan 2 hafta sonra hasta boyun ağrısı ve ses kısıklığından yakındı. TSH ve sT4 normaldi, anti-tiroid peroksidaz, anti-tiroglobülin, ESH ve CRP yükseldi. Sonografide sol lobta tiroidit izlendi. Hasta ibuprofen ile tedavi edildi. Takipte, hipotiroidizm tanısıyla levotiroksin başlandı. Dolayısıyla klinisyenler aşılanmış kişilerde SAT olasılığını akılda tutmalıdır. (Turkish) [ FROM AUTHOR] Copyright of Turkish Journal of Endocrinology & Metabolism is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
亚急性甲状腺炎(SAT)最近与严重急性呼吸综合征-冠状病毒-2感染或针对它的疫苗有关。我们报告一例41岁男性患者在冠状病毒病-2019 (COVID-19)疫苗接种后出现持续性SAT。他在第一剂COVID-19疫苗(CoronaVac®)后出现喉咙痛和颈部疼痛。近期无病毒感染史。红细胞沉降率(ESR)、c反应蛋白(CRP)升高，促甲状腺激素(TSH)、游离甲状腺素(fT4)正常，COVID-19聚合酶链反应试验阴性，超声示右叶甲状腺炎。甲强的松龙治疗后症状消失。然而，在第二次接种疫苗2周后，患者出现颈部疼痛和声音嘶哑。TSH、fT4正常，但抗甲状腺过氧化物酶(anti- TPO)、抗甲状腺球蛋白(anti- tg)、ESR、CRP升高。超声显示左叶甲状腺炎。病人用布洛芬治疗。在随访中，诊断为甲状腺功能减退，并开始使用左旋甲状腺素。因此，临床医生应该怀疑接种疫苗的受试者中存在SAT的可能性。(中文)[来源]Subakut tiroidit (SAT)， son zamanlarda iddetli akut solunum sendromu- koronavir -2 enfeksiyonu veya buna kar ilygeli tirilen aşılarla ili kilendirilmektedir。koronavir s hastalığı- 2019[冠状病毒病-2019 (COVID-19)] aşılaması sonrasında persistan SAT geli 41 yaşında erkek hastamızı sunuyoruz。COVID-19 aşısının (CoronaVac®)ilk dozundan sonra boğaz ağrısı ve boyun ağrısı ile ba vurdu。Yakın zamanda病毒enfeksiyon öyküsü yoktu。利特沙沉积症hızı (ESH) ve C-reaktif蛋白(CRP) y ksekti, tiroidstim促生激素(TSH) ve serbest tiroksin (sT4)正常，COVID-19聚合锌(zir) reaksiyonu检测阴性，超声心动图salaklota tiroidit mecuttu。甲替尼唑酮可引起症状性痴呆。安卡aşının12月2日，hafta sonra hasta boyun ağrısı ve ses kısıklığından yakındı。TSH ve sT4正常，抗类固醇peroksidaz，抗tiroglobine, ESH ve CRP y kseldi。超声心动图是一种有效的治疗方法。哈斯塔布洛芬是我的父亲。Takipte, hipotiroidizm tanısıyla左旋roksin ba。Dolayısıyla klinisyenler aşılanmış ki ilerde SAT olasılığını akılda tutmalıdır。(土耳其)[来自作者]土耳其内分泌与代谢杂志版权所有是Galenos Yayinevi Tic的财产。有限公司未经版权所有者的明确书面许可，STI及其内容不得复制或通过电子邮件发送到多个网站或发布到listserv。但是，用户可以打印、下载或通过电子邮件发送文章供个人使用。这可以删节。对副本的准确性不作任何保证。用户应参阅原始出版版本的材料的完整。(版权适用于所有人。)
{"title":"Persistent Subacute Thyroiditis Post SARS-CoV-2 Vaccine in a Male Patient with Positive Thyroid Autoantibodies","authors":"Ö. Topaloğlu, Sakin Tekin, Seda Nur Topaloğlu, T. Bayraktaroğlu","doi":"10.25179/tjem.2021-86594","DOIUrl":"https://doi.org/10.25179/tjem.2021-86594","url":null,"abstract":"Subacute thyroiditis (SAT) has been recently associated with severe acute respiratory syndrome-coronavirus-2 infection or vaccines against it. We report a case of a 41-year-old male patient who developed persistent SAT after the coronavirus disease-2019 (COVID-19) vaccination. He presented with sore throat and neck pain after the first dose of the COVID-19 vaccine (CoronaVac®). There was no history of a recent viral infection. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were elevated, thyroidstimulating hormone (TSH) and free thyroxine (fT4) were normal, COVID-19 polymerase chain reaction test was negative, and sonography showed thyroiditis in the right lobe. The symptoms resolved after treatment with methylprednisolone. However, 2 weeks after the second dose of the vaccine, the patient suffered from neck pain and hoarseness. TSH and fT4 were normal, but anti-thyroid peroxidase (anti- TPO), anti-thyroglobulin (anti-Tg), ESR, and CRP were elevated. Sonography revealed thyroiditis in the left lobe. The patient was treated with ibuprofen. On follow-up, hypothyroidism was diagnosed, and levothyroxine started. Hence, the clinicians should suspect the possibility of SAT in the vaccinated subjects. (English) [ FROM AUTHOR] Subakut tiroidit (SAT), son zamanlarda şiddetli akut solunum sendromu-koronavirüs-2 enfeksiyonu veya buna karşı geliştirilen aşılarla ilişkilendirilmektedir. Koronavirüs hastalığı- 2019 [coronavirus disease-2019 (COVID-19)] aşılaması sonrasında persistan SAT gelişen 41 yaşında erkek hastamızı sunuyoruz. COVID-19 aşısının (CoronaVac®) ilk dozundan sonra boğaz ağrısı ve boyun ağrısı ile başvurdu. Yakın zamanda viral enfeksiyon öyküsü yoktu. Eritrosit sedimentasyon hızı (ESH) ve C-reaktif protein (CRP) yüksekti, tiroidstimüle edici hormon (TSH) ve serbest tiroksin (sT4) normaldi, COVID-19 polimeraz zincir reaksiyonu testi negatifti ve sonografide sağ lobta tiroidit mevcuttu. Metilprednizolon tedavisi ile semptomlar geriledi. Ancak aşının 2. dozundan 2 hafta sonra hasta boyun ağrısı ve ses kısıklığından yakındı. TSH ve sT4 normaldi, anti-tiroid peroksidaz, anti-tiroglobülin, ESH ve CRP yükseldi. Sonografide sol lobta tiroidit izlendi. Hasta ibuprofen ile tedavi edildi. Takipte, hipotiroidizm tanısıyla levotiroksin başlandı. Dolayısıyla klinisyenler aşılanmış kişilerde SAT olasılığını akılda tutmalıdır. (Turkish) [ FROM AUTHOR] Copyright of Turkish Journal of Endocrinology & Metabolism is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)","PeriodicalId":425605,"journal":{"name":"The Turkish Journal of Endocrinology and Metabolism","volume":"87 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131416737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.25179/tjem.2019-65597
Fereshteh Rezaie, Delara Laghousi, M. Alizadeh
D O I: 10 .2 51 79 /t je m .2 01 965 59 7 Objective: The aim of this study was to determine the factors contributing to non-adherence to medication and nonmedication treatments among diabetic patients. Material and Methods: This cross-sectional study was conducted in family medicine clinics in Tabriz, Northwest of Iran, from May-September of 2018. The Persian version of the eight-item Morisky Medication Adherence Scale was used to assess the adherence to treatment, and a validated questionnaire was used to determine the factors influencing non-adherence to treatment. We analyzed the data using descriptive statistics, t-test, chi-square test, and logistic regression modeling. Results: A total of 320 diabetic patients were included in this study with a mean age of 58.1±13.7 years, with 36.2% males and 63.8% females. Of the patients, 0.9%, 14%, and 85% of patients had high, moderate, and low adherence to medication, respectively. In univariate logistic regression, the factors that associated with high adherence to treatment were female gender, living alone, living in urban, lacking insurance, and having diabetic complications. In contrast, in multivariate logistic regression, only two factors associated with high adherence to treatment, namely, living alone (odds ratio, 3.29; 95% confidence interval: 1.44– 7.94) and unemployment odds ratio, 0.085; 95% confidence interval: 0.008–0.9). Conclusion: Adherence to treatment in our study population was suboptimal. Our study population specified the lack of places for physical activity and difficulty in maintaining diet as major barriers for adherence to treatment. We also identified occupation and living arrangement to be predictive factors for adherence to treatment.
{"title":"Medication Adherence and Associated Factors Among Type II Diabetic Patients in East Azerbaijan, Iran","authors":"Fereshteh Rezaie, Delara Laghousi, M. Alizadeh","doi":"10.25179/tjem.2019-65597","DOIUrl":"https://doi.org/10.25179/tjem.2019-65597","url":null,"abstract":"D O I: 10 .2 51 79 /t je m .2 01 965 59 7 Objective: The aim of this study was to determine the factors contributing to non-adherence to medication and nonmedication treatments among diabetic patients. Material and Methods: This cross-sectional study was conducted in family medicine clinics in Tabriz, Northwest of Iran, from May-September of 2018. The Persian version of the eight-item Morisky Medication Adherence Scale was used to assess the adherence to treatment, and a validated questionnaire was used to determine the factors influencing non-adherence to treatment. We analyzed the data using descriptive statistics, t-test, chi-square test, and logistic regression modeling. Results: A total of 320 diabetic patients were included in this study with a mean age of 58.1±13.7 years, with 36.2% males and 63.8% females. Of the patients, 0.9%, 14%, and 85% of patients had high, moderate, and low adherence to medication, respectively. In univariate logistic regression, the factors that associated with high adherence to treatment were female gender, living alone, living in urban, lacking insurance, and having diabetic complications. In contrast, in multivariate logistic regression, only two factors associated with high adherence to treatment, namely, living alone (odds ratio, 3.29; 95% confidence interval: 1.44– 7.94) and unemployment odds ratio, 0.085; 95% confidence interval: 0.008–0.9). Conclusion: Adherence to treatment in our study population was suboptimal. Our study population specified the lack of places for physical activity and difficulty in maintaining diet as major barriers for adherence to treatment. We also identified occupation and living arrangement to be predictive factors for adherence to treatment.","PeriodicalId":425605,"journal":{"name":"The Turkish Journal of Endocrinology and Metabolism","volume":"75 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121372627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.25179/tjem.2019-71974
C. Idiz, S. Celik, Elif Bagdemir, M. Dişsiz, I. Satman
Objective: Education is the cornerstone of diabetes management, and numerous educational studies used Diabetes Knowledge Level Tests to determine the effectiveness of education. Our study was planned to adopt the revised Diabetes Knowledge Test (DKT2) of the Michigan Diabetes Research and Training Center for the Turkish population. Material and Methods: A total of 296 diabetic subjects using insulin were included in the study. After the determination of the validity of the language and content of the test, it was applied to the patients. The reliability of the study was assessed using Cronbach’s alpha coefficient. The results of the DKT2 demographic values, and laboratory tests of the patients were noted. Results: Cronbach’s alpha values were 0.60, 0.59, and 0.70 for the first part, second part, and complete test, respectively. The test-retest reliability values were 0.76 and 0.87 (p<0.001), respectively. The correct response rate to the first part was 32.68±2.47% in patients with Type 1 diabetes and 32.16±2.66% in patients with Type 2 diabetes using insulin. The correct response rate to the second part was 19.68±2.05% and 19.55±2.96%, respectively. Discussion: The Turkish adapted version of DKT2 is a reliable tool to measure patients’ level of diabetes knowledge. However, in order to increase the level of knowledge of the patients, education of diabetes should be improved.
{"title":"Turkish Adaptation of Michigan Diabetes Research and Training Center’s Revised Diabetes Knowledge Test and Determination of Factors Affecting the Knowledge Level of Diabetic Individuals","authors":"C. Idiz, S. Celik, Elif Bagdemir, M. Dişsiz, I. Satman","doi":"10.25179/tjem.2019-71974","DOIUrl":"https://doi.org/10.25179/tjem.2019-71974","url":null,"abstract":"Objective: Education is the cornerstone of diabetes management, and numerous educational studies used Diabetes Knowledge Level Tests to determine the effectiveness of education. Our study was planned to adopt the revised Diabetes Knowledge Test (DKT2) of the Michigan Diabetes Research and Training Center for the Turkish population. Material and Methods: A total of 296 diabetic subjects using insulin were included in the study. After the determination of the validity of the language and content of the test, it was applied to the patients. The reliability of the study was assessed using Cronbach’s alpha coefficient. The results of the DKT2 demographic values, and laboratory tests of the patients were noted. Results: Cronbach’s alpha values were 0.60, 0.59, and 0.70 for the first part, second part, and complete test, respectively. The test-retest reliability values were 0.76 and 0.87 (p<0.001), respectively. The correct response rate to the first part was 32.68±2.47% in patients with Type 1 diabetes and 32.16±2.66% in patients with Type 2 diabetes using insulin. The correct response rate to the second part was 19.68±2.05% and 19.55±2.96%, respectively. Discussion: The Turkish adapted version of DKT2 is a reliable tool to measure patients’ level of diabetes knowledge. However, in order to increase the level of knowledge of the patients, education of diabetes should be improved.","PeriodicalId":425605,"journal":{"name":"The Turkish Journal of Endocrinology and Metabolism","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121380912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：